I've never seen a buyout that was bad news. LOL. IMO the value of ATL to any buyer is at least 75 cents maybe as high as 90 cents. You also got it wrong about Amplats. They do not have a stake in ATL. Amplats and ATL own a mining operation together. Amplats is considering selling their portion of the mine if they can get a premium price. That would be great for ATL if that happens.
ECTE was $40 two years ago. Platinum said today they are looking for a return to $30 at least once they are in charge.
Ask Laurel Hill
GOOG following ECTE imho. Needles are going the way of horse buggies.
The latest project from Google X is a smart contact lens, a tiny, flexible computer capable of monitoring glucose levels in tears. Researchers at Google are hopeful that one day this technology might be used to help diabetes patients better control their disease.
"I think the Google X device could be a huge game changer," says Dr. John Buse, professor of medicine at the University of North Carolina School of Medicine. He's also chairman of the National Diabetes Education Program for the National Institutes of Health and the Centers for Disease Control and Prevention.
Buse and Google researchers are quick to point out that years of basic research remain before this device or one like it comes to market. At the moment, even the relationship between the level of glucose in tears and blood glucose levels remains unproven.
Nonetheless, the tiny wireless computer embedded on a soft contact lens represents a remarkable technical achievement.
Scientists at Google unveiled their prototype Thursday.
"At this point, we have functional prototypes," said Brian Otis, the project lead at Google X. "We have integrated circuits that have been miniaturized to the point where they look like a piece of glitter integrated inside the soft contact lens material."
The smart lens consists of this glitter-fleck-sized wireless computer chip as well as a microscopically small glucose sensor and an antenna thinner than a human hair. All of this is embedded between two layers of soft-contact lens material.
"We have a glucose sensor that has to be much more sensitive — because the concentration of glucose in tears is much lower than the concentration in blood. We've also created a way of tying all of these technologies together in a flexible platform," Otis said — so flexible and soft that you could slip it over your eye.
A loan? Fat chance. They have no cash flow to repay a loan. Negative assets and net worth. No bank would touch them. The offering will be priced at the normal 20% discount. Look for a deal around 2.40 imho.
The old timers have been saying for months there will me multiple partners overseas. No one company covers all the markets. I do think we will see the first one announced soon but you never know for sure. glty
this one could be off to the races
Do you think they talked about it on CNBC because they had nothing else to do? A buyout is the end game. Big pharmas are snatching up these small drug developers every day and NAVB will get bought. You will see.